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Abstract
Background: Polyglutamine diseases constitute a class of neurodegenerative disorders associated with expansion
of the cytosine-adenine-guanine (CAG) triplet, in protein coding genes. Expansion of a polyglutamine tract
in the N-terminal of TBP is the causal mutation in SCA17. Brain sections of patients with spinocerebellar ataxia 17
(SCA17), a type of neurodegenerative disease, have been reported to contain protein aggregates of TATA-binding
protein (TBP). It is also implicated in other neurodegenerative diseases like Huntington’s disease, since the protein
aggregates formed in such diseases also contain TBP. Dysregulation of miR-29a/b is another common feature
of neurodegenerative diseases including Alzheimer’s disease, Huntington’s disease, and SCA17. Using a cellular
model of SCA17, we identified key connections in the molecular pathway from protein aggregation to miRNA
dysregulation.
Methods: Gene expression profiling was performed subsequent to the expression of TBP containing polyglutamine
in a cellular model of SCA17. We studied the expression of STAT1 and other interferon-gamma dependent genes in
neuronal apoptosis. The molecular pathway leading to the dysregulation of miRNA in response of protein aggregation
and interferon release was investigated using RNAi-mediated knockdown of STAT1.
Results: We show that the accumulation of polyglutamine-TBP in the cells results in interferon-gamma release which
in turn signals through STAT1 leading to downregulation of miR-29a/b. We propose that the release of interferons by
cells harboring toxic protein aggregates may trigger a bystander effect resulting in loss of neurons. Interferon-gamma
also led to upregulation of miR-322 although this effect is not mediated through STAT1.
Conclusions: Our investigation shows that neuroinflammation could be an important player in mediating the
transcriptional dysregulation of miRNA and the subsequent apoptotic effect of toxic polyglutamine-TBP. The
involvement of immunomodulators in polyglutamine diseases holds special therapeutic relevance in the light
of recent findings that interferon-gamma can modulate behavior.
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Background
Polyglutamine diseases are caused by expansion of
polymorphic cytosine-adenine-guanine (CAG) triplets
in protein coding regions of the genome resulting in
aggregation-prone proteins. Accumulation of nuclear
protein aggregates has been demonstrated in several
polyglutamine diseases [1–4]. These diseases show
some common features like increased severity in pa-
tients with longer expansions and anticipation, i.e., an
earlier age of onset in subsequent generations [4].
However, each of the known polyglutamine diseases
results in neuronal cell death in distinct parts of the
brain. The pathological range of the causative triplet
repeats expansions differ widely and occur in genes
with no apparent functional overlap. For instance,
Huntington’s disease is caused by expansion of the
polyglutamine stretch beyond 35 repeats, in the pro-
tein Huntingtin, resulting in striatal and cortical neu-
ronal cell death [5], while Spinocerebellar Ataxia 17 is
caused by mutations of a stretch of more than 42
polyglutamines in the general transcription factor,
TATA-binding protein, resulting in loss of cerebellar
neurons [6].
TBP, a general transcription factor, has been found in the
nuclear aggregates in postmortem brain tissue of patients
of Huntington’s disease (HD) [7] and Spinocerebellar
ataxias like (SCA1, SCA2, and SCA3) [8]. TBP has also
been found in aggregates of Alzheimer’s disease (AD) [9]
as well as neuronal intranuclear hyaline inclusion disease
(NIH-ID) [10], suggesting that besides its direct involve-
ment in SCA17, TBP is also affected in other neurode-
generative diseases. Gene expression studies from other
groups and ours have pointed to transcriptional dysregula-
tion in polyglutamine diseases [11, 12].
We have previously shown that expression of
polyglutamine-expanded TBP in mouse neuronal cells
is associated with formation of intra-nuclear protein ag-
gregates and cell death [12]. Expression profiling of
microRNAs during this process revealed temporal
changes that match in vivo findings in mice and pa-
tients [13]. The downregulation of miR-29a/b was a key
step in the molecular pathway leading to apoptotic cell
death since transient knockdown of the miRNA-
induced partial cell death in cultured cells [13]. Brain
specific, transient knockdown of the miRNA was suffi-
cient to induce ataxia-like behavior in mice [14], while
stable knockout of the miRNA resulted in smaller
Purkinje cells with reduced dendritic arborization, loco-
motor impairment, and ataxia–distinctive features seen
in SCA17 transgenic mice models [15]. The downre-
gulation of miR-29a/b is not restricted to SCA17 but is
a general feature of several neurodegenerative diseases
including Alzheimer’s disease, Huntington’s disease,
and schizophrenia [16]. Besides neurodegenerative diseases,
neuronal apoptosis is accompanied by downregulation
of miR-29a/b during embryonic stages of brain deve-
lopment [17].
miR-29a/b plays a critical role in neuronal survival, but
the events that modify the expression of these regulatory
RNAs during neurodegeneration are not known. Identifi-
cation of regulatory molecules that control the expression
of miR-29a/b in neurons could provide insight into patho-
logical mechanisms. Using the cellular model of SCA17,
we explored the molecular pathway that leads to downre-
gulation of miR-29a/b following the expression of polyglu-
tamine containing TBP. We carried out gene expression
profiling in this cellular model of SCA17 and found
that a set of five co-regulated genes was induced in
polyglutamine-TBP containing cells. The genes include
STAT1, a key transcriptional regulator, and four genes
that are known to be induced by interferon-gamma
(IFN-γ). Here, we show that the induction of STAT1 is
necessary and sufficient to cause the previously re-
ported downregulation of miR-29a/b during neuronal
apoptosis. Besides miR-29a/b, we show that the IFN-γ
mediated signaling also resulted in upregulation of
miRNA, miR-322 through a STAT1 independent mech-
anism. This study establishes a sequence of events from
polyglutamine aggregation to transcriptional dysregula-
tion through cell signaling and consequent loss of anti-
apoptotic miRNA expression leading to cell death in
cells expressing toxic polyglutamine-TBP.
Methods
Cell culture and transfection
Neuro-2a cells (mouse neuroblastoma cell line; ATCC
number CCL-131; N2a) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen) supple-
mented with 10% fetal calf serum (Invitrogen), 2 mM L-
glutamine (Sigma), 1 mM sodium pyruvate (Sigma), and
antibiotic-antimycotic solution (100X stock) (Invitrogen)
at 37 °C humidified incubator with 5% CO2. Transfection
was performed using Amaxa nucleofection technology
and following the manufacturer’s protocol. 106 cells and
3 μg of plasmid DNA were used for transfection. Trans-
fection efficiency was calculated by counting GFP positive
cells, which came out to be ~50%.
RNA isolation and microarray
Total RNA from Neuro-2a cells (24, 36, and 60 h post-
transfection) was isolated using Trizol reagent following
the manufacturer’s protocol. Microarray experiments
were done using mouse Genome 430 2.0 (GeneChip).
Briefly, 100 ng of total RNA was used for labeling reac-
tion. Labeling, hybridization, and washing steps were
performed following the manufacturer’s protocol.
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Data analysis
Microarray hybridization was carried out with three bio-
logical replicates for both 16Q-TBP and 59Q-TBP ex-
pressing cells. Background correction was performed and
features flagged for low expression were removed before
data was normalized using quantile normalization. For
each probe, at every time point, a t test was used to test
the null hypothesis that the expression level between
16Q-TBP and 59Q-TBP was unchanged. At the same
time, the average intensity level for all replicate spots for
every probe was calculated for 16Q-TBP and 59Q-TBP
and the fold change was estimated. Probes for which the
difference between samples was greater than 1.5 fold and
at least one time point had a t test significance level less
than 0.05/315 = 1.59 × 10−4 were selected.
Transfection and luciferase assay
Neuro-2a cells, seeded in a 96-well plate at about 20,000
cells per well and grown for 24 h, were co-transfected with
constructs as indicated in the results using Lipofectamine
(Invitrogen) as per manufacturer’s protocol. Twenty-four
hours after transfection, cells were lysed in 20 μl of passive
lysis buffer (Promega). The luciferase assay was performed
using a Dual-Luciferase assay kit (Promega), and lumi-
nescence was measured in a microplate Luminescence
counter (Top count NXT PerkinElmer). For data analysis,
Renilla luciferase was normalized to firefly luciferase.
Cytochrome c assay
Cells were scraped, washed in 1XPBS, resuspended in 1×
extraction buffer A containing 10 mM HEPES, pH 7.5,
200 mM mannitol, 70 mM sucrose and 1 mM EGTA
(Sigma) and 2 mg per ml bovine serum albumin (Sigma)
and kept on ice for 1 h. Cells were lysed by a B-type
Dounce homogenizer, and homogenates were centrifuged
at 4 °C in the subsequent steps to remove nuclei, debris,
and mitochondria. To obtain the cytosolic fraction,
supernatant was centrifuged at 15,000 g at 4 °C. The
cytochrome c concentration in the cytosolic fraction
was quantified by solid phase ELISA kit (Quantikine
Rat/Mouse, R & D systems) according to the manu-
facturer’s protocol.
Real-time PCR for miRNA-29a/b
For-real time PCR experiments, total RNA was iso-
lated from Neuro-2a/HeLa cells using TRIzol reagent
(Invitrogen) following the manufacturer’s protocol. Mouse
brain was micro dissected into three different parts, cere-
bellum, cortex, and hippocampus. For real-time PCR, total
RNA was isolated by crushing brain parts in TRIzol re-
agent using liquid nitrogen followed by manufacturer’s
protocol. For cDNA synthesis and real-time PCR TaqMan
assay (Applied Biosystems; Cat. No. 000412[miR-29a],
000413[miR-29b], 000430[miR-92]) specific for mature
mmu-miR-29a, mmu-miR-29b and mmu-miR-92 was
used. mmu-miR-92 was used as endogenous control. Rela-
tive quantification method was used for data analysis.
For Stat1, Usp18, Gbp3, Cxcl10, and Isg15, cDNA was
prepared using gene-specific reverse primers and M-MuLV
reverse transcriptase (NEB) at 42 °C for 1 h. Real-time
PCR was performed using gene specific primers and SYBR
green master mix (Roche). The sequences are given below:
Induction of IFN-γ
One hunderd units/ml of mouse recombinant IFN-γ
was exogenously added to Neuro-2a cells. Briefly, 106
cells were seeded 1 day prior to induction. Next day,
100 units of IFN-γ dissolved in PBS + 0.1%BSA was
added per ml of media and kept at 37 °C. PBS + 0.1%BSA
was used as control.
Reporter assay for IFN-γ
Reporter assay was performed using Cignal GAS Reporter
(luc) Kit: CCS-009 L (Qiagen) as per manufacturer’s pro-
tocol. Briefly, 20,000 cells were seeded in each well of a 96-
well plate. Next day cells were transfected with 16Q-TBP/
59Q-TBP constructs along with the GAS-responsive firefly
luciferase construct along with Renilla luciferase expres-
sing construct and kept at 37 °C for 24, 36, and 60 h. Post-
transfection, dual-luciferase assay was performed using
dual-luciferase kit (Promega).
Spent media and neutralizing IFN-γ antibody experiments
Neuro-2a cells were transfected with 16Q-TBP and
59Q-TBP constructs and kept at 37 °C for 36 h. Post-
transfection media from these cells was taken and put
on untransfected Neuro-2a cells, these cells were further
incubated at 37 °C for 24 h. For neutralizing IFN-γ ex-
periments, similar transfections were done, and 36-h
post transfection 2 μg/ml of IFN-γ antibody (abcam-
ab10745) was added and kept at 37 °C for 12 h. Media
from these cells was applied to untransfected Neuro-2a
cells and kept for 24 h.
Over-expression and knockdown of Stat1, miR-322
For over-expression of mouse Stat1, 2.5 kb of mouse
Stat1 CDS was cloned under CMV promoter using
Gene Forward primer Reverse primer Product
size (bp)
Stat1 GCTGTGCCTCTGGAATGATG CGGGAGCTCTCACTGAATCT 110
Usp18 CCTTGTCTGCTGCATTTCAA TTCCGTGTGTGAGCTTTCAG 120
Gbp3 GCATCTCCTGTGGAGCTTTC TCACTCCCTTCCTCAGCACT 105
Isg15 AAGAAGCAGATTGCCCAGAA TCGCTGCAGTTCTGTACCAC 149
Cxcl10 TCCTTGTCCTCCCTAGCTCA ATAACCCCTTGGGAAGATGG 124
18srRNA CCTCCAATGGATCCTCGTTA CTTTCGAGGCCCTGTAATTG 63
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pEGFPN3 plasmid (Promega). The sequence for primers
is given below:
Stat1 FP: ATATCTCGAGCGGAGACAGCCCAGTAAGTC
Stat1 RP: ATATGGATCCCAGCASTGCTCAGCAAATGT
For knockdown experiments, 100 nM of Stat1siRNA
(sigenome)/negative control siRNA was transfected into
Neuro-2a cells for 48 h. ON-TARGET plus non-targeting
siRNA (Thermo scientific D-001810-01) was used as nega-
tive control. miR-322 was cloned from mouse genomic
DNA using primers flanking the pre-miRNA sequences.
The amplified product of approximately 110 bp was cloned
in pSilencer 4.1 CMV Neo Vector using BamHI and
HindIII sites.
Results
To understand the global gene expression changes occur-
ring in SCA17 condition, we performed microarray expe-
riments using the Affymetrix platform in the previously
reported cellular model of SCA17. Neuro-2a cells were
transiently transfected with two alternative constructs,
with contain TBP, with a stretch of 16 (normal, 16Q) or
59 (pathogenic, 59Q) contiguous glutamine residues as a
C-terminal fusion. As reported in our previous papers, we
found that the pathogenic protein formed intra-nuclear
aggregates, the expression of miR-29a/b was downregulated
in a time-dependent manner, and the 59Q-TBP containing
cells showed increased apoptosis [12–14]. In agreement
with our previous studies using cDNA microarrays [12], we
did not find a general reduction in global gene expression
changes in polyglutamine-TBP containing cells. Both eleva-
tion and reduction of expression of specific genes at all
three time points (24, 36, and 60 h) post transfection of
expanded polyglutamine-TBP construct was observed.
Interestingly, Signal Transducer and Activator of Tran-
scription1 (Stat1) and its four dependent genes, Ubiquitin
Specific Proteases18 (Usp18), Guanylate Binding Protein3
(Gbp3), Interferon Stimulated Gene15 (Isg15), and C-X-C
motif chemokine10 (Cxcl10) were found to be significantly
up regulated in Neuro-2a cells expressing polyglutamine-
TBP condition (Fig. 1a).
To validate the result obtained from microarray analysis,
real-time PCR was performed for all the five differentially
expressed genes. Neuro-2a cells were transfected with
plasmids expressing 16Q-TBP and 59Q-TBP, and qRT-
PCR was done for five genes (Stat1, Usp18, Gbp3, Isg15,
and Cxcl10) using gene specific primers (Fig. 1b). Stat1
mRNA was mildly induced at 24 h, while downstream
Stat1-dependent genes such as Usp18, Gbp3, Isg15, and
Cxcl10 were all induced at 36 h (Fig. 1b, c).
Gamma activating sequences (GAS) elements are up-
stream to genes that respond to IFNγ signaling by
binding to activated STAT1 dimers. We checked the
time-dependent effect of 59Q-TBP on a reporter con-
struct with tandem GAS elements fused to a luciferase
reporter (Fig. 1d). Cells with 59Q-TBP showed a strong
induction of the luciferase reporter indicating active
IFN signaling (Fig. 1e).
We then looked at differentially expressed genes iden-
tified in the microarray analysis and functionally classi-
fied them to assess genes involved in specific biological
processes. Upregulated genes showed significant en-
richment for interferon and immunity-related processes
(Table 1) while downregulated genes remained unclassi-
fied with no significant enrichment for any biological
process. Notably, IFN-γ induced protease, cytokines, and
ubiquitin-like proteins were found to be increased in
59Q-TBP.
To understand the relevance of the STAT1-dependent
genomic response, we studied the effects of Stat1 over-
expression and knockdown on cell death by measuring
cytochrome c release. For over expression studies, the
coding region of mouse Stat1 was cloned under CMV
promoter while siRNA against Stat1 was used for knock-
down experiments. The ectopic expression of STAT1 re-
sulted in a 10-fold upregulation of the steady state levels
of the STAT1 mRNA (Fig. 2a). The knockdown of Stat1,
by a STAT1 siRNA, was confirmed by real-time PCR
(Fig. 2b). Under these conditions, we found a 21% in-
crease in cytochrome c release (Fig. 2c). The STAT1
siRNA led to 60% downregulation of Stat1 mRNA, 40 h
post-transfection. We used the STAT1 siRNA to reverse
the elevated STAT1 levels in cells expressing the patho-
genic 59Q-TBP. The STAT1 siRNA could only partially
(28%) reverse the apoptosis, as indicated by cytochrome
c release (Fig. 2d).
We have previously reported the downregulation of
miR-29a/b and miRNA profiling in cells expressing
polyglutamine-TBP [13]. Besides the downregulation of
miR-29a/b, we have also shown that miR-322 was upre-
gulated concomitantly [13]. Under the same conditions,
we also found that STAT1 and its dependent genes were
upregulated. Therefore, we explored if the STAT1 over-
expression was linked to the downregulation of miR-29a/b
or upregulation of miR-322. We used IFN-γ to induce the
expression of STAT1 in Neuro-2a cells, independent of
polyglutamine-TBP. To establish the effect of IFN-γ in-
duction in cells, the mRNA levels of genes such as
Stat1 (Fig. 3a), Proteasome subunit beta type-9 (Psmb9)
(Fig. 3b), and Proteasome subunit beta type-8 (Psmb8)
(Fig. 3c) which are known markers of IFN-γ stimulation
were measured. All the three genes were found to be
significantly upregulated upon treatment of Neuro-2a
cells with IFN-γ, compared to control treated cells con-
firming the successful induction as well as downstream
signaling via this cytokine (Fig. 3) in Neuro-2a cells.
After verifying that STAT1 and several interferon gamma
dependent genes were induced as expected, we checked
the effect of IFN-γ treatment on the microRNAs, mmu-
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miR-29a/b using qRT-PCR. We found that mmu-miR-29a/
b was downregulated following IFN-γ treatment while
mmu-miR-322 was upregulated (Fig. 4a). We knocked
down Stat1 expression using siRNA against Stat1 mRNA
and monitored the effect on miR-29a/b (Fig. 4b). As ex-
pected, over-expression of Stat1 under a strong CMV pro-
moter resulted in the downregulation of both miR-29a and
miR-29b (Fig. 4c), thus establishing that miR-29a/b is
under direct transcriptional repression by STAT1. To con-
firm that STAT1 was required for the downregulation of
miR-29a/b in polyglutamine-TBP cells, we simultaneously
transfected the polyglutamine constructs and siRNA
against STAT1. The siRNA against Stat1 resulted in 48%
reduced expression of Stat1. Under these Stat1-depleted
conditions, miR-29a/b was not significantly downregulated
in 59Q-TBP cells, compared to 16Q-TBP (Average fold
change of miR-29a = 1.07 ± 0.19; p value = 0.48; n = 3;
miR-29b = 1.1 ± 0.32; p value = 0.38, n = 3).
We have previously reported that miR-322 was in-
duced in polyglutamine-TBP expressing cells [13]. To
test if miR-322 affects apoptotic cell death triggered by
polyglutamine toxicity, we cloned and over-expressed
the pre-miR-322. We found that the over-expression of
miR-322 resulted in elevated caspase 3 activity and cyto-
chrome c release indicating increased apoptosis (Fig. 5a,
b). Although polyglutamine-TBP and IFN-γ treatment
independently led to the induction of miR-322 (Fig. 5c),
over-expression and knockdown of STAT1 had no effect
on miR-322 expression (Fig. 5d) in the cells, even when
done in the background of TBP-59Q and TBP-16Q
(Average fold change = 1.01 ± 0.18; p value = 0.9). We
reasoned that IFN-mediated induction of miR-322 was
not mediated through STAT1. This was also corrobo-
rated by the absence of GAS sites upstream to miR-322.
Further, it agrees well with our finding that siRNA-
mediated mitigation of STAT1 could only partially res-
cue the apoptotic effect of polyglutamine-TBP.
Next we sought to identify events upstream to STAT1
induction in polyglutamine-TBP mediated miRNA dys-
regulation. We had noticed that the mRNA and miRNA
dysregulation, be it induction of STAT1 or miR-322 and
downregulation of miR-29a/b, were all reverted to nor-
mal levels following a change of media, suggesting that a
secreted factor is responsible for the mRNA and miRNA
expression changes. To test this hypothesis directly, we
treated Neuro-2a cells with the spent media collected
from 16Q or 59Q-TBP expressing cells (Fig. 6a). Media
collected from 59Q-TBP-containing cells that were
undergoing apoptosis could also induce STAT1 expres-
sion (Fig. 6b), downregulation of miR-29a/b expression
in Neuro-2a cells (Fig. 6c, d). Since this effect was not
seen in spent media of 16Q-TBP cells, we reasoned that
polyglutamine expansion results in secretion of the fac-
tor into the surrounding media, which is in turn may be
Fig. 1 Differential expression of Stat1 and its dependent genes. Neuro-2a cells were transfected with 16Q-TBP or 59Q-TBP and total RNA compared by
microarray analysis (a) or qRT-PCR (b, c) at indicated times (24, 36, and 60 h post transfection). Relative expression indicates fold change with respect
to expression at 24 h post transfection. Reporter assay for IFN-γ dependent upregulation was studied by co-transfecting GAS promoter-
luciferase reporter fusion plasmid (d) in Neuro-2a cells. Induced GAS promoter activity in the presence of 59Q–TBP (e). (n = 3; *p value
<0.05; **p value ≤ 0.01; ***p value ≤ 0.001)
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sufficient to trigger cell death, even in cells that have
never expressed polyglutamine-TBP. Neutralizing anti-
bodies against IFN-γ could suppress the effect of the
spent media, partially restoring miR-29a but not miR-
29b, suggesting that IFN-γ is the likely signaling factor
released by polyglutamine-TBP containing neurons.
Taken together, our results suggest that neuronal cells
expressing polyglutamine-TBP release interferons into
the surrounding milieu which through a cascade of sig-
naling events triggers the induction of STAT1 and sub-
sequent downregulation of miR-29a/b. The interferon
signaling also leads to the upregulation of miR-322, an-
other dysregulated miRNA in polyglutamine-TBP cells,
but this is independent of STAT1. Exogenously added
interferon-gamma in the medium, spent media from the
apoptotic cells or STAT1 over-expression, are sufficient
to trigger miR-29a/b down regulation and apoptosis.
Discussion
Here, by integrating the gene expression changes in
mRNA and miRNA during polyglutamine-TBP mediated
toxicity, we present a holistic view of molecular changes
that potentially occur in SCA17. It is proposed that
polyglutamine-TBP protein on aggregation induces inter-
feron production in neurons. This interferon perhaps in
conjugation with factors released by glia induces STAT1
and lead to downstream gene expression changes. A key
effect of STAT1 induction is the repression of miR-29a/b
that leads to previously established cascade of events
marked by over-expression of apoptotic genes including
Vdac1, Bace1, Puma, and Bak. IFN-γ neutralization in the
spent media rescues miR-29a level but not miR-29b level.
We concur that steady state levels of miR-29b seem to be
recalcitrant to the spent media and the neurtralization of
IFN therein. This is perhaps because miR-29 isoforms
are coded for by two genes—the first encodes miR-29a
and b-1 (Human: chr7:130,876,567-130,877,750; Mouse:
chr6:31,062,609-31,063,227) and second encodes miR-
29b and c (Human: chr1:207,801,476-207,802,623; Mouse:
chr1:195,036,808-195,037,705). Thus, the miR-29b levels
detected in the qRT-PCR are a combined effect of the
two miR-29b genes. Moreover, miR-29b is known to be
nuclear-localized and have distinct turnover dynamics
that may render it recalcitrant to the effect of the neu-
tralizing antibody. Although predicted STAT1 binding
sites were noticed upstream to the miR-29a/b1 gene,
we could not unequivocally demonstrate the direct
binding of STAT1 at these sites. In publicly available
ENCODE data, enrichment of STAT1 in the hsa-miR-
29a/b promoter region is evident [18, 19].
STAT1-Dependent Genomic Response of Neurons has
been studied extensively in the context of viral infections
that lead to neurodegeneration [20]. STAT1 is also known
to be involved in brain injury by regulating expression of
proteins which contribute to cell death [21] (Takagi et al.,
[22]). However, the role of STAT1-mediated gene re-
gulation has not been previously implied in inherited
neurodegenerative diseases. Our studies show that, the
downregulation of miR-29a/b, a common event in many
neurodegenerative diseases like Alzheimer’s disease [23],
Huntington’s disease [24], and Spino-cerebellar ataxia17
[16] is under the regulation of STAT1.
STAT1 is a key transcriptional mediator of interferon
signaling pathways, leading to upregulation at the vast
majority of target promoters, but can also switch to a re-
pressive role at some promoters in association with spe-
cific partners that alter the specificity of heterodimeric
STAT1 [25, 26]. In our study, the effect of interferon
was only partially mediated through STAT1 suggest-
ing that there are yet unknown players in this cellular
pathway that connect polyglutamine toxicity to anti-
apoptotic miRNAs.
Interferon-gamma is known to be intricately involved
with miR-29a/b in a feedback regulatory loop in immune
cells [27, 28]. However, the role of interferon signaling
and its effects on miR-29a/b regulation in neuronal cells
have not been studied before. Our results suggest that
Table 1 List of differentially expressed interferon-related genes
and log fold changes at 36 h in 59Q-TBP condition compared
to 16Q-TBP
Gene Function Log2 (Fold Change)
Gbp3 Interferon gamma induced Guanylate
binding protein
2.37
Tyki Thymidine kinase induced by interferon
in antiviral response
2.16
Ifih1 Interferon-induced helicase 2.12
Rsad2 Interferon-induced antiviral protein 2.12
Samd9l Sterile alpha motif domain-containing
protein 9-like
1.99
Isg15 Interferon-stimulated protein similar to
ubiquitin like molecules
1.97
Rsad2 Interferon-induced antiviral protein 1.84
Oas1c Interferon induced, involved in response
to viral infection
1.81
Oasl2 Interferon induced, involved in response
to viral infection
1.78
Igtp Interferon gamma inducible GTP binding
protein
1.69
Psmb9 Interferon gamma induced protease 1.68
Cxcl10 Interferon gamma induced cytokine 1.65
Stat1 Interferon induced transcriptional factor 1.63
Apol9A Interferon induced apolipoprotein 1.58
Usp18 Interferon induced ubiquitin specific
peptidases
1.54
Rtp4 Interferon-induced receptor transporter
protein
1.53
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polyglutamine toxicity can trigger inter-cellular signaling
by interferons resulting in two levels of response. Firstly,
the secreted cytokines can bring about transcriptional
changes in the cells carrying the polyglutamine protein.
More interestingly, the cytokines can also lead to a by-
stander effect on other neurons. Speculating further, in
the patient brain, neuron-glia crosstalk might lead to a
further exacerbation of the bystander effect. A response
originally evolved for destroying cells with a toxic build-
up of protein aggregates perhaps triggers an uncontrolled
bystander effect leading to the loss of a larger num-
ber of neurons.
IFN signaling in the brain was originally studied in the
context of viral infections which trigger the release of in-
terferons [29]. Once activated by interferons, STAT1 ho-
modimer enters the nucleus and binds to cis-regulatory
elements known as GAS elements containing a consensus
sequence TTCN(2-4)GAA, to initiate or suppress tran-
scription of IFN-regulated genes [30, 31]. In Alzheimer’s
disease, the involvement of IFN-γ is well established [32],
Fig. 3 Neuro-2a responds to IFN-γ signaling. Neuro-2a treated with 100 units/ml of mouse recombinant IFN-γ or Phosphate buffered saline (PBS) were
monitored using qRT-PCR at indicated times post-treatment to study the response of Stat1 (a), Psmb9 (b), Psmb8 (c) genes (n = 3)
Fig. 2 Stat1 over-expression leads to neuronal cell death. Neuro-2a cells were transfected with Stat1 expressing plasmid (STAT1-pEGFP-N3) or vector
(control plasmid) (a) and negative control siRNA or siRNA against Stat1 (b). Real-time PCR was done to check the expression of Stat1 after 24 h under
these conditions. Stat1 over-expression induced cytochrome c release while siRNA against Stat1 was sufficient to partially rescue the increased
cytochrome c release (c, d). Neuro-2a cells were transfected with Stat1 over expressing and control plasmid, 24 h post transfection, cytosolic
protein was isolated, and cytochrome c assay was done (c). Cells were co-transfected with 16Q-TBP/59Q-TBP constructs along with control
siRNA and siRNA against Stat1 for 48 h, and after isolation of cytosolic protein fraction cytochrome c assay was done. (n = 3; **p value ≤ 0.01)
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although ambiguous, since IFN-γ infusion shows both
enhanced neurogenesis and aggravated pathology in trans-
genic mice models [33–35]. It is pertinent to note that
downregulation of miR-29a/b, perhaps in response to
IFN-γ, has been reported in Alzheimer’s disease pathology
both in animal models and in patients [23, 36]. Notably,
interferons are used as therapeutic agents in the treatment
of auto-immune diseases of the central nervous system,
for instance, multiple sclerosis [37, 38]. IFN-γ is one of the
primary cytokines produced by CD8+T cells [39] as well
as microglia in brain in response to stroke [40], brain in-
jury [41], as well as in multiple sclerosis [42]. Recently,
Filipino et al. have suggested that interferon signaling may
be closely associated with neurological and psychiatric
deficits seen in pathological conditions [43]. At the mo-
lecular level, they also showed conclusively that neurons
and microglia express receptors to IFN-γ. The receptors
allow the cells to respond to IFN-γ by increasing number
Fig. 5 miR-322 over-expression can induce apoptosis in Neuro-2a cells: (a) The caspase-3 activity in Neuro-2a cells transfected with vector
(control) or miR-322 clone (miR-322) was monitored at the time indicated (24, 36, 60 h post transfection). At 24 h, under the same conditions
(b) relative cytochrome c release was elevated. IFN-γ treatment also led to the induction of miR-322 levels in qRT-PCR based assay (c). Stat1
knockdown (by Control or Stat1 siRNA) and over-expression (by Vector or Stat1-pEGFP-N3) has no significant effect on expression of miR-322 (d)
Fig. 4 Neuro-2a cells modulate miRNA expression in response to IFN-γ treatment. a Neuro-2a cells treated with IFN-γ (100 units/ml) induced
mmu-miR-322 and repressed mmu-miR-29a/b expression. b Stat1 knockdown using siRNA leads to upregulation of miR-29a/b. Neuro-2a cells
were treated for 24 h with non-targeting siRNA or Stat1 siRNA. c Stat1 over-expression leads to decrease in miR-29a/b expression (n = 3; **p
value ≤0.01)
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of c-fos positive cells in mouse cortex [43]. Our results
in the context of these in vivo findings highlight the
need for studying IFN signaling in specific regions of
well-established transgenic mice models of polygluta-
mine diseases.
Conclusions
Gene expression profiling revealed STAT1 and four
genes namely Usp18, Gbp3, Isg15, and Cxcl10 were
upregulated in polyglutamine-TBP conditions. Integrat-
ing changes in mRNA and miRNA expression, we
found that interferon signaling is critical to the down-
regulation of miR-29a/b and upregulation of miR-322.
Our results strongly indicate that release of interferons
by neuronal cells expressing polyglutamine-TBP leads
to induction of STAT1 and consequent downregulation
of miR-29a/b by a series of cell signaling events. On the
other hand, interferon-mediated upregulation of miR-
322 did not require STAT1, implying that further inves-
tigation will lead to identification of other key players
in pathways connecting polyglutamine toxicity and the
role of miRNAs in neuronal apoptosis. The involve-
ment of interferon signaling in cellular mechanisms of
polyglutamine-TBP mediated toxicity reveal the key
role of neuro-inflammation in SCA17 pathogenesis.
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